Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Ribonucleic Acid (RNA) Therapy Clinical Trials Research Report 2026: $3.4 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

globenewswire.com
PFE Pfizer Inc. is mentioned as a key market player in the growing RNA therapy clinical trials market, indicating its involvement in the sector without specific positive or negative news. AZN AstraZeneca plc is listed as a key player in the RNA therapy clinical trials market. The article highlights the market's growth, implying potential opportunities for companies like AstraZeneca. NVS Novartis AG is highlighted for its strategic acquisition of DTx Pharma for $1 billion, significantly enhancing its RNA-based therapeutics pipeline, particularly for neurological disorders. This acquisition signals strong positive momentum. GSK GlaxoSmithKline plc is identified as a key market player in the expanding RNA therapy clinical trials sector. The article focuses on market growth drivers and trends, positioning GSK within this positive outlook. MRNA Moderna Inc. is mentioned as a key participant in the RNA therapy clinical trials market. The article's overall positive outlook on market growth suggests potential benefits for companies like Moderna.

Ribonucleic Acid (RNA) Therapy Clinical Trials Research Report 2026: $3.4 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F Dublin, April 24, 2026 (GLOBE NEWSWIRE) -- The "Ribonucleic Acid (RNA) Therapy Clinical Trials Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The RNA therapy clinical trials market is witnessing steady growth, with projections indicating an increase from $2.7 billion in 2025 to $3.4 billion by 2030, reflecting a CAGR of 4.7%. This expansion is largely driven by advancements in RNA delivery technologies, enhanced funding for rare diseases and cancer research, and the rising adoption of personalized medicine. Significant collaborations between biotech and pharma companies further bolster this growth, alongside an expanding global network for clinical trials.

The increasing incidence of infectious diseases is a major factor propelling the market. RNA-based clinical trials are integral to the development of targeted treatments for emerging pathogens, demonstrated by a reported increase in HIV cases in specific demographics, highlighting the evolving need for adaptive medical solutions.

Key market players include Pfizer Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., and others. Notably, in July 2023, Novartis AG acquired DTx Pharma for $1 billion, enhancing their RNA-based therapeutics pipeline through the integration of DTx Pharma's FALCON platform. This acquisition underscores the strategic emphasis on expanding capabilities in RNA-based treatments for neurological disorders.

RNA therapy innovations such as antisense oligonucleotide therapies are gaining traction, targeting specific genetic sequences for precise treatment of genetic and rare diseases. Sepul Bio's recent initiation of the LUNA Phase 2b trial for ultevursen, targeting exon 13 mutations of the USH2A gene, is a testament to the innovative efforts in this domain.

Geographically, North America was the leading region in 2025, yet Asia-Pacific is projected to exhibit the fastest growth. The market encompasses diverse regions, including Western and Eastern Europe, South America, and the Middle East, fostering a dynamic global landscape.

Tariffs have influenced the market by escalating costs for imported materials like nucleotides and specialized equipment, primarily impacting North America and Europe. However, these challenges stimulate local sourcing and innovation, nurturing the development of cost-effective RNA therapy platforms.

This market report provides a comprehensive analysis of the RNA therapy clinical trials landscape, offering insights into market size, regional shares, competitive dynamics, and emerging trends. It highlights modalities such as RNA interference, mRNA therapies, and antisense approaches, covering various therapeutic areas from oncology to neurological disorders.

The market's value includes services such as RNA therapeutic administration and genetic testing. Revenue figures are based on the geographical location of consumption, emphasizing local market dynamics irrespective of production origins.

In conclusion, the RNA therapy clinical trials market is poised for substantial growth, driven by technological advancements, increased funding, and strategic industry partnerships, presenting significant opportunities for stakeholders.

Key Attributes:

Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market Trends

Report Scope

Markets Covered:

Subsegments and Companies Mentioned:

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/zg8ylj

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment